stockrowNovo Nordisk A/S
NVO Healthcare Drug Manufacturers General
Novo Nordisk A/S’s revenue for fiscal 2025 (year ended December 2025) was $46.8 billion, up 11.1% from fiscal 2024.
- Revenue
- +4.47%
- EPS
- −18.7%
- Free cash flow
- +71.6%
- Total debt
- +44.4%
Quarter to June 2026, against a year earlier
Follow NVO
Alert me
Novo Nordisk A/S (NVO) EBITDA
Novo Nordisk A/S's EBITDA for fiscal 2025 was $22.7B, up 5.97% from $21.4B in fiscal 2024. Over the twelve months to 30 June 2026 it was $26.5B. Over the past ten years it has ranged from $7.7B (fiscal 2016) to $22.7B (fiscal 2025) — the current reading is the highest in ten years. EBITDA has risen for 7 consecutive fiscal years. Novo Nordisk A/S ranks 4th of 20 Drug Manufacturers General companies by EBITDA.
EBITDA, annual
Embed this chart
Annual newest first
| Period | EBITDA | Change |
|---|---|---|
| FY2025 | $22.7B | 5.97% |
| FY2024 | $21.4B | 31.48% |
| FY2023 | $16.3B | 39.75% |
| FY2022 | $11.6B | 13.09% |
| FY2021 | $10.3B | 12.16% |
| FY2020 | $9.2B | 5.25% |
| FY2019 | $8.7B | 11.39% |
| FY2018 | $7.8B | (1.23%) |
| FY2017 | $7.9B | 3.26% |
| FY2016 | $7.7B | (1.62%) |
Quarterly newest first
| Period | EBITDA | Change |
|---|---|---|
| Jun 2026 | $5.8B | (41.25%) |
| Mar 2026 | $9.9B | 70.09% |
| Dec 2025 | $5.8B | 17.17% |
| Sep 2025 | $5.0B | (15.39%) |
| 42 more quarters | Free account |
Against its own ten years
EBITDA against peers
| Company | EBITDA |
|---|---|
| NVO Novo Nordisk A/S | $26.5B |
| NVS Novartis AG compare | $22.1B |
| AZN AstraZeneca PLC compare | $21.2B |
| PFE Pfizer Inc. compare | $20.1B |
| AMGN Amgen Inc. compare | $16.5B |
| BMY Bristol Myers Squibb Company compare | $14.1B |
| GSK GSK PLC Sponsored ADR compare | $12.2B |
| SNY Sanofi compare | $11.1B |
| GILD Gilead Sciences, Inc. compare | $451.0M |
What EBITDA is
EBITDA shows what a company earns from its operations before interest, taxes and the non-cash charges for depreciation and amortization.
Reported line item
More on NVO
- Revenue
- Net income
- EPS (diluted)
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement